Formation Bio
AI-native drug developer that skips discovery: in-licenses clinical-stage assets, runs development with AI, and holds each asset in its own subsidiary.
1. Core Product / Service
Formation Bio (New York; founded 2016 as TrialSpark) does no drug discovery. It in-licenses or acquires clinical-stage or clinic-ready assets, applies AI and in-house software to speed clinical development and operations, and holds each asset in a dedicated subsidiary (e.g. Libertas, Bleecker, Riverview, High Line) [1]. It monetizes by advancing and out-licensing — gusacitinib was sublicensed to Sanofi in June 2025 [1].
Current disclosed assets [1][2]:
| Asset | Origin | Status |
|---|---|---|
| BLKR201 (formerly LNK01006), CNS-penetrant TYK2 inhibitor | Licensed from Lynk Pharmaceuticals, Dec 2025 (worldwide ex-Greater China); held via Bleecker Bio | First participant dosed in a healthy-volunteer SAD/MAD Phase 1 in June 2026; data expected early 2027 [2] |
| Anti-CD226 antibody | IMIDomics; ulcerative colitis | IND in place |
| Gusacitinib | — | Sublicensed to Sanofi (June 2025) |
Wet lab: none disclosed — the model is development-only, so preclinical science sits with licensors and execution with clinical vendors (inferred from the business model; no lab facility has been reported) [1].
2. Target Users & Pain Points
- Licensors (often Asia-based biotechs such as Lynk) that need a Western development partner for ex-regional rights.
- Pharma partners (Sanofi) that buy de-risked assets, and an AI collaboration with Sanofi and openai to build R&D software [1].
- Pain addressed: clinical development — not discovery — is where most cost and time sit; Formation argues AI-run operations can move assets through trials faster and cheaper.
3. Competitive Landscape
| Player | Approach | Vs. Formation |
|---|---|---|
| insilico-medicine / recursion-pharmaceuticals | AI discovery → own clinical pipeline | Generate their own assets; Formation buys them |
| iambic-therapeutics | In-house AI discovery + CDMO/CRO downstream | Opposite end of the value chain |
| Asset-NewCo vehicles (e.g. Chinese-asset US NewCos) | License China assets into US shells | Similar sourcing; Formation adds an AI-operations layer |
4. Unique Observations
- Origin is often misdescribed: TrialSpark is frequently called a CRO, but it was a technology-driven clinical-trial service with its own site network that ran studies for drugmakers before pivoting to a pipeline model after its Series C [1][3].
- Pure "development-stage" bet: among AI-labelled biotechs, Formation is the clearest test of whether AI's value lies downstream (trial design, operations, regulatory) rather than in molecule design.
- Asset-per-subsidiary structure resembles BridgeBio-style hubs, isolating each program's financing and exit.
5. Financials / Funding
- Series C: $156M, led by Sam Altman and Lachy Groom; valuation reported above $1B [1].
- Series D: $372M (June 2024), led by a16z with Sanofi participating [4].
- Total: ~$530M (single-source estimate) [1]. No 2026 financing round was found as of 2026-10-14 [5].
6. People & Relationships
- Co-founders: Benjamine Liu (CEO; Rhodes Scholar), Linhao Zhang, Kit Dobyns.
- Board: Scott Kupor (a16z), Alfred Lin (Sequoia) [1].
- Partners: Sanofi, openai, Lynk Pharmaceuticals, IMIDomics.
- Investors: a16z, Sanofi, Sam Altman, Lachy Groom.
Sources
- [1] Formation Bio announcements and press coverage of licensing and partnerships (accessed 2026-10-14)
- [2] Formation Bio press release, first participant dosed with BLKR201 (2026-06; accessed 2026-10-14); Lynk licensing blog post (2025-12)
- [3] Endpoints News, "After years of running trials for other drugmakers, TrialSpark is building its own pipeline" (accessed 2026-10-14)
- [4] Pharmaceutical Technology, "Formation Bio secures $372M" (2024-06; accessed 2026-10-14)
- [5] Built In company profile (accessed 2026-10-14)